Clinical Trials
Dallas Research Institute is your community partner providing access to cutting edge care through clinical trials for fatty liver disease and associated metabolic disorders.
Our goal is to provide state-of-the-art clinical research trial opportunities and education to the community.
What is a Clinical Trial?
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about interventions. These include new treatments and known interventions that warrant further study and comparison.
Who Can Participate in a Clinical Trial?
Each trial has specific eligibility requirements. It is important to note that inclusion and exclusion criteria are used to identify appropriate participants, promote participants’ safety, and ensure that researchers are able to gather the information they need to address questions outlined in the study protocol.
Why Participate?
Participating in clinical research is a great way to learn more about your condition and potentially gain access to the latest treatments and medications. The treatment is provided at no cost to the volunteer and there is often compensation for time and travel.
You can help advance medical research and contribute to the development of new treatments and medications for others in your community.
Contact Dallas Research Institute today to learn more about our current enrolling studies.
Study Participants Receive
FibroScan® Liver Screening
Healthy Living Counseling
Time and Travel
Compensation*
Continuous Monitoring
Blood
Work
World-Class Care
*Compensation is study specific
The Clinical Trial Process
Clinical trials typically consist of four distinct phases, each serving a specific purpose in the research process.
PHASE I
Participants: 20 – 100
Duration: Several Months
The primary goal is to assess the safety and dose range of the new drug or treatment in a small number of patients. Participants are closely monitored for adverse effects.
PHASE III
Participants: 300 – 3,000
Duration: 1 – 4 Years
This phase involves even larger populations to compare the new treatment against existing standard treatments or placebo. The goal is to gather more comprehensive data on the treatment's effectiveness, safety and potential side effects.
PHASE II
Participants: Several Hundred
Duration: Several Months – 2 Years
The focus shifts to evaluating the treatment's effectiveness and further assessing its safety in a larger number of patients. Participants are closely monitored to assess the benefits and potential side effects.
PHASE IV
Post-Marketing Surveillance
Participants: Thousands
Duration: Highly Variable
This phase occurs after the treatment has been approved and made available to the public. Researchers continue to monitor its long-term safety and effectiveness.
